Antiscleroderma-70 antibodies
Antiscleroderma-70 antibodies-13355
Anti-Scl 70
ANTISCL70M
Semiquantitative result of IgG class
Differential diagnosis of scleroderma (progressive systemic sclerosis)
Submission of the minimum volume does not allow for repeat testing
Immediatley following collection, mix sample by gently inverting 5 times
- Allow sample to clot for a minimum of 30 minutes
- Spin within two (2) hours of sample collection
Gold serum separator (SST) tube
- Allow sample to clot
- Spin within two (2) hours of sample collection
- Transfer serum to a Transfer vial/tube with cap - 12mL (LabCorp), labelled as serum
Ambient (preferred) - 14 days
Refrigerated - 14 days
Frozen - 14 days
Hemolysis, icterus, lipemia, gross bacterial contamination
Multiplex flow immunoassay
0.0 - 0.9 AI
Scl-70 antibody is seen in 20% of patients with scleroderma, and in some patients with CREST syndrome (calcinosis, Raynaud, esophageal dysfunction, sclerodactyly, telangiectasia). These syndromes are also associated with a high frequency of speckled pattern immunofluorescent antinuclear antibody tests. Scl-70 may identify a subset of scleroderma patients with severe skin, joint, and lung disease. In addition, the presence of Scl-70 in Raynaud phenomenon may indicate a poor prognosis.